Clinical Research Directory
Browse clinical research sites, groups, and studies.
Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins
Sponsor: Oguz Arslanturk
Summary
This study evaluates whether calcium dobesilate, a venoactive drug, improves recovery after radiofrequency ablation (RFA) for varicose veins. Patients with great saphenous vein insufficiency undergoing RFA will be randomly assigned to receive either calcium dobesilate (500 mg twice daily) or standard care alone. The treatment starts 7 days before the procedure and continues for 30 days after. The primary outcome is postoperative pain at day 7. Secondary outcomes include pain at days 14 and 30, quality of life, ecchymosis, and return to daily activities.
Official title: Effect of Perioperative Calcium Dobesilate on Postprocedural Pain, Symptom Relief, and Quality of Life After Radiofrequency Ablation for Great Saphenous Vein Insufficiency: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2026-02-28
Completion Date
2026-11
Last Updated
2026-02-05
Healthy Volunteers
No
Interventions
calcium dobesilate
Calcium dobesilate 500 mg oral tablet, twice daily (morning and evening), starting 7 days before radiofrequency ablation and continuing for 30 days postoperatively. Total treatment duration is 37 days.
Locations (1)
Zonguldak Bulent Ecevit University Hospital, Department of Cardiovascular Surgery
Kozlu, Zonguldak Province, Turkey (Türkiye)